|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial显示文摘AIM: To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC). METHODS: Randomized patients received cetuximab with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (FOLFOX) 6 (arm A, n = 74) or 5-FU, FA and irinotecan (FOLFIRI) (arm B, n = 77). KRAS mutation status was determined retrospectively in a subset of tumors (n = 117). RESULTS: No significant difference was found between treatment arms A and B in the progression-free survival (PFS) rate at 9 mo, 45% vs 34%; median PFS, 8.6 mo vs 8.3 mo [hazard ratio (HR) = 1.06]; overall response rate (ORR) 43% vs 45% [odds ratio (OR) = 0.93] and median overall survival (OS), 17.4 mo vs 18.9 mo (HR = 0.98). Patients with KRAS wild-type tumors demonstrated improved PFS (HR = 0.55, P = 0.0051), OS, (HR = 0.62, P = 0.0296) and ORR (53% vs 36%) and in arm A, improved PFS (HR = 0.49, P = 0.0196), OS (HR = 0.48, P = 0.0201) and ORR (56%vs 30%), compared with patients with KRAS mutated tumors. In arm B no significant differences were found in efficacy by KRAS mutation status. Treatment in arms A and B was generally well tolerated. CONCLUSION: This study confirms that combinations of cetuximab with FOLFOX6 or FOLFIRI are effective and significantly improve clinical outcome in KRAS wild-type compared with KRAS mutated mCRC. | Janja Ocvirk Thomas Brodowicz Fritz Wrba Tudor E Ciuleanu Galina Kurteva Semir Beslija Ivan Koza Zsuzsanna Pápai Diethelm Messinger Ugur Yilmaz Zsolt Faluhelyi Suayib Yalcin Demetris Papamichael Miklós Wenczl Zrinka Mrsic-Krmpotic Einat Shacham-Shmueli Damir Vrbanec Regina Esser Werner Scheithauer Christoph C Zie-linski | 2010 | World Journal of Gastroenterology2010，16，25： | 17 |
| 2 | A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy显示文摘 | Gy?rgy Bodoky Constanta Timcheva David Spigel Phillip Stella Tudor Ciuleanu G. Pover N. Tebbutt | 2012 | Investigational New Drugs2012，，3： | 2 |
| 3 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial显示文摘 | Edward B Garon Tudor-Eliade Ciuleanu Oscar Arrieta Kumar Prabhash Konstantinos N Syrigos Tuncay Goksel Keunchil Park Vera Gorbunova Ruben Dario Kowalyszyn Joanna Pikiel Grzegorz Czyzewicz Sergey V Orlov Conrad R Lewanski Michael Thomas Paolo Bidoli Shaker | 2014 | The Lancet2014，，： | 2 |
| 4 | Erlotinib in previously treated non-small-cell lung cancer 显示文摘 | Shepherd FA Rodrigues Pereira J Ciuleanu T | 2005 | N Engl J Med2005，353，2： | 1 |
| 5 | Phase Ⅲ trial comparing supportive care alone with supportive care with oral to-potecan in patients with relapsed small cell lung cancer 显示文摘 | O'Brien ME Ciuleanu TE Tsekov H | 2006 | J Clin Oncol2006，24，： | 1 |
| 6 | Optimizing treat-ment for patients with metastatic renal cell carcinoma in the Centraland Eastern European region 显示文摘 | Vrdoljak E Ciuleanu T Kharkevich G | 2012 | Expert Opin Pharmacother2012，13，2： | 1 |
| 7 | Erlotinib in previ- ously treated non- small -cell lung cancer显示文摘 | Shepherd FA Rodrigues PJ Ciuleanu T | 2005 | N Engl J Med2005，353，2： | 1 |
| 8 | Erlotinib as mainte- nance treatment in advanced non-small-cell lung cancer: a multi- centre, randomised, placebo-controlled phase 3 study 显示文摘 | Cappuzzo F Ciuleanu T Stelmakh L | 2010 | Lancet oncol2010，11，6： | 1 |
| 9 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)显示文摘 | Nick Thatcher Alex Chang Purvish Parikh José Rodrigues Pereira Tudor Ciuleanu Joachim von Pawel Sumitra Thongprasert Eng Huat Tan Kristine Pemberton Venice Archer Kevin Carroll | 2005 | The Lancet . 2005 (9496)2005，，9496： | 1 |
| 10 | Phase Ⅲ trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer显示文摘 | O'Brien ME Ciuleanu TE Tsekov H | 2006 | J Clin Oncol2006，24，34： | 1 |
| 11 | Erlotinib in previously treated non-small-cell lung cancer显示文摘 | Shepherd FA Rodrigues pereira J Ciuleanu T | 2005 | N Engl J Med2005，353，2： | 1 |
| 12 | Erlotinib in previously treated non-small-cell lung cancer 显示文摘 | Shepherd F A Rodfigues Pereira J Ciuleanu T | 2005 | N EngL J Med2005，353，2： | 1 |
| 13 | Erlotinib in previ-ously treated non-small cell lung cancer 显示文摘 | Shepherd FA Rodrigues J Ciuleanu T | 2005 | N Engl J Med2005，353，5： | 1 |
| 14 | Phase Ⅲ trial comparing supportive carealone with supportive carewith oral topotecan in patients with relapsed small-cell lung cancer显示文摘 | O'Brien ME Ciuleanu TE Tsekov H | 2006 | J Clin Oncol2006，24，34： | 1 |
| 15 | Phase Ⅲ trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer显示文摘 | O'Brien ME Ciuleanu TE Tsekov H | 2006 | J Clin Oncol2006，24，34： | 1 |
| 16 | Erlotinib in previously treated non-small cell lung cancer显示文摘 | Shepherd FA Rodrigues Pereira J Ciuleanu T | 2005 | N Engl J Med2005，353，： | 1 |
| 17 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer:a randomised,double-blind,phase 3 study显示文摘 | Ciuleanu T Brodowicz T Zielinski C | | 0，，： | 1 |
| 18 | A randomized, double-blind, phase m trial of ramucirumab, a VEGFR-2 monoclonal antibody, plus Docetaxel versus placebo plus Docetaxel for second-line treatment of non-small cell lung cancer 显示文摘 | Ciuleanu TE Arrieta O Prabhash K | 2014 | J Clin Oucol2014，32，15： | 1 |
| 19 | Erlotinib in previ- ously treated non-small-cell lung cancer显示文摘 | Shepherd FA Rodrigues Pereira J Ciuleanu T | 2005 | N Engl J Med2005，353，： | 1 |
| 20 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study显示文摘 | Ciuleanu T Brodowicz T Zielinski C | 2009 | Lancet2009，374，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员